Nanobiotix Announces Trading Halt on Euronext Paris for Global Equity Offering Pricing

On May 21, 2026, Nanobiotix S.A. announced a temporary trading halt of its ordinary shares on Euronext Paris. The halt, requested by the company, began at 9:00 a.m. CEST to facilitate the pricing and allocation process for a global equity offering. This Global Offering consists of two components: a public offering of American Depositary Shares (ADSs) in the United States and a concurrent offering of ordinary shares and pre-funded warrants to qualified investors in Europe and other international jurisdictions. The suspension of trading is intended to allow for the formal confirmation of investor allocations and the final pricing of the securities. Nanobiotix expects trading on Euronext Paris to resume at approximately 3:30 p.m. Paris time (9:30 a.m. New York time) on the same day, following a subsequent communication. Nanobiotix is a late-stage clinical biotechnology company focused on physics-based therapeutic approaches in oncology and other major diseases. The filing does not disclose the specific number of shares to be sold or the expected proceeds from the offering.